Analyst Price Targets — ALNY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 28, 2026 12:48 pm | — | Jefferies | $230.00 | $233.50 | TheFly | Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data |
| August 25, 2026 7:31 am | Jeffrey Walch | Bernstein | $376.00 | $236.01 | StreetInsider | Bernstein SocGen Group Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY) |
| August 18, 2026 8:19 pm | — | BMO Capital | $318.00 | $228.61 | TheFly | Alnylam initiated with an Outperform at BMO Capital |
| August 14, 2026 10:30 am | Derek Archila | Wells Fargo | $256.00 | $227.12 | TheFly | Alnylam price target lowered to $256 from $316 at Wells Fargo |
| August 4, 2026 2:20 pm | — | H.C. Wainwright | $455.00 | $215.61 | TheFly | Alnylam price target lowered to $455 from $485 at H.C. Wainwright |
| August 4, 2026 11:24 am | — | Truist Financial | $315.00 | $220.33 | TheFly | Alnylam price target lowered to $315 from $410 at Truist |
| August 3, 2026 9:16 am | Eliana Merle | Barclays | $450.00 | $205.52 | TheFly | Alnylam price target lowered to $450 from $527 at Barclays |
| July 31, 2026 12:31 pm | Martin Auster | Raymond James | $420.00 | $203.31 | TheFly | Alnylam price target lowered to $420 from $468 at Raymond James |
| July 31, 2026 12:09 pm | Luca Issi | RBC Capital | $350.00 | $203.29 | StreetInsider | Alnylam Pharma. (ALNY) PT Lowered; RBC Capital: 'Tough Update But Stock Reaction Looks Overdone' |
| July 31, 2026 11:55 am | — | Oppenheimer | $350.00 | $205.48 | TheFly | Alnylam price target lowered to $350 from $500 at Oppenheimer |
Latest News for ALNY
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 8:45 AM ET in Everett, Massachusetts Morgan Stanley 24th Annual Global Healthcare Conference on Monday,…
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twenty-four research firms that are covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong
[url="]Alnylam Pharmaceuticals, Inc[/url]. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALNY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.